Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Healthy

Interventions

DRUG

Placebo to dose

placebo

DRUG

Idarucizumab

short infusion

DRUG

Placebo to Idarucizumab

DRUG

dabigatran

2 capsules dabigatran

DRUG

Idarucizumab

short infusion

Trial Locations (1)

1321.5.00001 Boehringer Ingelheim Investigational Site, Sumida-ku, Tokyo